Cargando…
Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study
BACKGROUND: Neuromyelitis optica (NMO) spectrum disorder (NMOSD) is a devastating autoimmune inflammatory disorder of the central nervous system, which can result in blindness or paralysis. Currently, there is a dire need for new treatment options in the clinic. Several case series have shown that m...
Autores principales: | Jiao, Yujuan, Cui, Lei, Zhang, Weihe, Zhang, Chunyu, Zhang, Yeqiong, Zhang, Xin, Jiao, Jinsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911949/ https://www.ncbi.nlm.nih.gov/pubmed/29688841 http://dx.doi.org/10.1186/s12883-018-1056-x |
Ejemplares similares
-
Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
por: Zhang, Weihe, et al.
Publicado: (2023) -
Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
por: Lin, Jie, et al.
Publicado: (2022) -
Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
por: Huang, Qiao, et al.
Publicado: (2018) -
Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis
por: Songwisit, Sakdipat, et al.
Publicado: (2020) -
Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report
por: Zhang, Weihe, et al.
Publicado: (2022)